Docket No.: PF-0487-2 DIV

## **Certificate of Mailing**

"Express Mail" mailing label number EV 330 963 947 US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated and is addressed to: Mail Stop: Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on July 21, 2003.

By: Diane Kizer Printed: Diane Kizer

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Lal et al.

Title:

**HUMAN E1-LIKE PROTEIN** 

Serial No.:

To Be Assigned

Filing Date:

Herewith

Examiner:

To Be Assigned

Group Art Unit:

To Be Assigned

Mail Stop: Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants wish to call to the attention of the Examiner the enclosed "List of References Cited by Applicants." The right is reserved to antedate any item in accordance with standard procedure.

Applicants respectfully submit under 37 C.F.R. 1.98(3)(d) that copies of references 1-20are not included herein as copies were previously cited by or submitted to the Office in parent application Serial No. 09/039,064 filed March 13, 1998, from which we are claiming priority under 35 U.S.C. 120.

Citation of the documents is not to be construed as an admission that the documents are necessarily prior art with respect to the instant invention. This submission is understood to complement the results of the Examiner's own independent search. Citation of the documents shall not be construed as a representation that a search has been made or that the cited items are inclusive of all the relevant and material citations that may be available publicly. Any NCBI report included herein may not have an accurate date for prior art purposes. Some of the documents may have markings thereon. No significance is meant to be attached to the markings.

Applicants respectfully request that the cited documents be considered by the Examiner and that an initialed copy of the List of References Cited by Applicants be returned to Applicants.

112450

Docket No.: PF-0487-2 DIV

It is believed that this disclosure complies with 37 CFR §§ 1.56, 1.97 and 1.98 and the Manual of Patent Examining Procedures § 609. If for some reason the Examiner considers otherwise, please telephone the undersigned.

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. 09-0108.

If there are any questions regarding the above, the Examiner is invited to call the undersigned.

Respectfully submitted,

INCYTE CORPORATION

Michelle M. Stempien

Reg. No. 41,327

Direct Dial Telephone: (650) 843-7219

Customer No.: 27904 3160 Porter Drive

Palo Alto, California 94304 Phone: (650) 855-0555

Fax: (650) 845-4166

112450 2

U.S. Department of Commerce, Patent and Trademark Office	Atty Docket No.	Serial No.	
	PF-0487-2 DIV	To Be Assigned	
LIST OF REFERENCES CITED BY APPLICANTS	Applicant(s)		
(Use several sheets if necessary)	Lal et al.		
	Filing Date	Group	
	To Be Assigned	To Be Assigned	

			U.S.	Patent Documents				
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing I If Appro	
			Foreig	n Patent Documents	<u> </u>		//////////////////////////////////////	1 a t i a a
		Document	Date	Country	Class	Subclass	Yes	lation No
		Documente	Ducc	Country	Class	Subclass	ies	NO
					<u> </u>			
	ОТІ	HER ART (In	cluding Auth	nor, Title, Date,	Pertinen	t Pages, E	tc.)	
	1	HER ART (Including Author, Title, Date, Pertinent Pages, Etc.)  Ciechanover, A. The Ubiquitin-Proteasome Proteolytic Pathway. Cell 79:13-21  (1994).						
	2	Rolfe, M. et al. The ubiquitin-mediated proteolytic pathway as a therapeutic area. <b>J. Mol. Med.</b> 75:5-17 (1997).						
	3	Jentsch, S. THE UBIQUITIN-CONJUGATION SYSTEM. Annu. Rev. Genet. 26:179-207 (1992).						
	4	Wilson, R. et al. 2.2 Mb of contiguous nucleotide sequence from chromosome III of <i>C. elegans</i> . <b>Nature</b> 368:32-38 (1994).						
	5	Dohmen, R.J. et al. An Essential Yeast Gene Encoding a Homolog of Ubiquitinactivating Enzyme. <b>J. Biol. Chem.</b> 270:18099-18109 (1995).						
	6	Stephen, A.G. et al. Identification of a Region within the Ubiquitin-activating Enzyme Required for Nuclear Targeting and Phosphorylation.  J. Biol. Chem. 272:10895-10903 (1997).						
	7	Nagai, Y. et al. Ubiquitin-activating enzyme, E1, is phosphorylated in mammalian cells by the protein kinase Cdc2. <b>J. Cell Sci.</b> 108:2145-2152 (1995).						
	8	Lenk, S.E. et al. Ubiquitin-activating Enzyme, E1, Is Associated with Maturation of Autophagic Vauoles. J. Cell Biol. 118:301-308 (1992).						
	9	Kay, G.F. et al. A candidate spermatogenesis gene on the mouse Y chromosome is homologous to ubiquitin-activating enzyme E1. Nature 354:486-489 (1991).						
	10	Muller, S. and L.M. Schwartz. Ubiquitin in homeostasis, development and disease. <b>Bioessays</b> 17:677-684 (1995).						
	11	Chow, N. et	al. APP-BPI,	a Novel Protein T ecursor Protein.	That Bin	ds to the (	Carboxyl-1 11339-113	terminal 346

12	Wilson, R. et al., (Direct Submission), GenBank Sequence Database (Accession 1055197), National Center for Biotechnology Information, National Library of Medicine, Bethesda, Maryland, 20894. (GI 1055197).
13	Wilson, R. et al., (Direct Submission), GenBank Sequence Database (Accession U40187), National Center for Biotechnology Information, National Library of Medicine, Bethesda, Maryland, 20894. (GI 1055194; GI 1055195; GI 1055196; GI 1055197; GI 1055198).
14	Dohmen, R.J. et al., (Direct Submission), GenBank Sequence Database (Accession 793879), National Center for Biotechnology Information, National Library of Medicine, Bethesda, Maryland, 20894. (GI 793879)
15	Dohmen, R.J. et al., (Direct Submission), GenBank Sequence Database (Accession Z48725), National Center for Biotechnology Information, National Library of Medicine, Bethesda, Maryland, 20894. (GI 793878; GI 793879)
 16	Ciechanover, A. et al. 'Covalent Affinity' Purification of Ubiquitin-activating Enzyme. <b>J. Biol. Chem.</b> 257:2537-2542 (1982).
17	Hillier, L. et al., GenBank EST Sequence Database (Accession N99449), National Center for Biotechnology Information, National Library of Medicine, Bethesda, Maryland, 20894. (GI 1271000), April 12, 1996.
18	Adams, M.D. et al., Genbank EST Sequence Database (Accession AA311634), National Center for Biotechnology Information, National Library of Medicine, Bethesda, Maryland, 20894. (GI 1963963), April 19, 1997.
19	Hillier, L. et al., Genbank EST Sequence Database (Accession AA780421), National Center for Biotechnology Information, National Library of Medicine, Bethesda, Maryland, 20894. (GI 2839752), February 5, 1998.
20	Hillier, L. et al., Genbank EST Sequence Database (Accession H08013), National Center for Biotechnology Information, National Library of Medicine, Bethesda, Maryland, 20894. (GI 872835), June 23, 1995.

Examiner	Date Considered